$39.38
+1.10(2.89%)
Mkt Cap $2.1B
$7.06
$39.61
52-Week Range
At A Glance
1
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer.
2
Most recently: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 1, 2 (2026-04-02).
$2.1B
Market Cap
—
Revenue
-$108M
Net Income
Employees60
Fundamentals
How The Business Makes Money
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001863127
ISINUS90240B1061
CUSIP90240B106
Phone619 728 4760
Address2656 State Street, Carlsbad, CA, 92008, US
SEC EDGAR